Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Celgene Corporation    CELG   US1510201049

CELGENE CORPORATION (CELG)

124
Delayed Quote. Delayed Nasdaq - 09/02 04:00:00 pm
95.09 USD   +0.07%
9h ago CELGENE : VentiRx Pharmaceuticals Provides Corporate and Clinical Update
5d ago UK cancer drug fund gets extra 160 million pounds
5d ago Pharmacyclics Appoints Chief Commercial Officer
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

04/25/2013 | 08:25am US/Eastern
Recommend:
0
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

Recommend :
0
React to this article
Latest news on CELGENE CORPORATION
9h ago CELGENE : VentiRx Pharmaceuticals Provides Corporate and Clinical Update
5d ago UK cancer drug fund gets extra 160 million pounds
5d ago Pharmacyclics Appoints Chief Commercial Officer
6d ago BRISTOL MYERS SQUIBB : and Celgene Enter Clinical Collaboration Agreement to Eva..
08/21 CELGENE : to Present at Investor Conferences in September
08/21 PHARMACYCLICS : Hires Chief Commercial Officer
08/21 CELGENE : Acceleron Pharma Posts 2Q Results
08/19 CELGENE : Lance Brings 21st Century Cures Initiative to New Jersey
08/19 CELGENE : Clinical Study in the Journal of Clinical Oncology Reports Patients wi..
08/19 Pharmacyclics Appoints Chief Commercial Officer
Advertisement
Chart
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Income Statement Evolution
Celgene Corporation : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF